A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid

被引:52
作者
Exner, T [1 ]
Joseph, J [1 ]
Low, J [1 ]
Connor, D [1 ]
Ma, D [1 ]
机构
[1] St Vincents Hosp, Dept Haematol, Darlinghurst, NSW 2010, Australia
关键词
phospholipid; procoagulants; platelets; microparticles; lupus anticoagulant; activated factor X; clotting test;
D O I
10.1097/00001721-200312000-00015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An improved activated factor X-based clotting method was used to investigate activity of procoagulant phospholipid (PPL) in blood samples collected into various anticoagulants and in plasmas with a range of abnormalities. The dilute activated factor X-activated clotting time (XACT) was carried out on a mixture of specimen with phospholipid-free porcine plasma. PPL from the test sample is then rate-limiting, controlling the clotting time so that the XACT is shortened from a maximum of approximately 120 s with citrated platelet-free plasma to approximately 30 s with freeze-thawed platelet-rich plasma. XACT results were only shortened slightly by fresh normal platelet-rich plasma, but were shortened significantly by platelets that had been activated by freeze-thawing. This improved method for PPL was not prolonged by deficiencies of known clotting factors and therapeutic levels of heparin, and it was surprisingly resistant to most lupus anticoagulants. However, it was extremely sensitive to PPL, detecting down to 50 ng/ml synthetic phospholipid added to phospholipid-free plasma. Excellent correlation was achieved between XACT shortening and microparticle count assessed by annexin V-binding and flow cytometry in normal plasma spiked with platelet microparticles. In citrated blood specimens, XACT shortened with time in a temperature-dependent manner. XACT results on blood samples anticoagulated with ethylenediamine tetra-acetate were more stable, and these would be preferable for assessing PPL expression ex vivo. XACT was significantly shorter in whole blood samples than in normal platelet-rich or platelet-poor plasmas, suggesting that PPL was normally expressed more by cells or aggregates larger than platelets or microparticles. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:773 / 779
页数:7
相关论文
共 25 条
  • [1] BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
  • [2] BRANDT JT, 1991, THROMB HAEMOSTASIS, V66, P453
  • [3] Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia
    Cappellini, MD
    Robbiolo, L
    Bottasso, BM
    Coppola, R
    Fiorelli, G
    Mannucci, PM
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (02) : 467 - 473
  • [4] FANTL P., 1958, AUSTRALIAN JOUR EXPTL BIOL AND MED SCI, V36, P499, DOI 10.1038/icb.1958.54
  • [5] GALLI M, 1992, THROMB HAEMOSTASIS, V68, P297
  • [6] Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves
    Geiser, T
    Sturzenegger, M
    Genewein, U
    Haeberli, A
    Beer, JH
    [J]. STROKE, 1998, 29 (09) : 1770 - 1777
  • [7] Gemmell CH, 1998, J BIOMED MATER RES, V42, P611, DOI 10.1002/(SICI)1097-4636(19981215)42:4<611::AID-JBM18>3.0.CO
  • [8] 2-D
  • [9] KAOLIN CLOTTING TIME OF PLATELET-RICH PLASMA - A TEST OF PLATELET FACTOR-3 AVAILABILITY
    HARDISTY, RM
    HUTTON, RA
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1965, 11 (03) : 258 - &
  • [10] Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186